Company Profile
TOT BIOPHARM is dedicated to becoming the industry leading and trusted
biopharmaceutical best partner for global clients.
With extensive practical experience, mature technical platforms and
robust quality system, TOT BIOPHARM has developed diversified strategic
partnerships with domestic and international pharmaceutical companies to
provide one-stop CDMO solutions for drug development and manufacturing, which
help customers to accelerate the development and manufacturing of biologics,
especially antibody-drug conjugates (ADCs), empowering to achieve high-quality
development for the industry.
TOT BIOPHARM (Stock Code: 1875.HK) was successfully listed on the Main
Board of The Stock Exchange of Hong Kong Limited on 8 November 2019, which
marks the Company's formally entrance into the international capital market.